Dopaminergic neurons protected from degeneration by GDNF gene therapy

Science

Volumn 275, Issue 5301, 1997, Pages 838-841

  Choi Lundberg, Derek L ^a   Lin, Qing ^a   Chang, Yung Nien ^b   Chiang, Yawen L ^b   Hay, Carl M ^b   Mohajeri, Hasan ^a   Davidson, Beverly L ^c   Bohn, Martha C ^a  

^a UNIVERSITY OF ROCHESTER   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROTROPHIC FACTOR; OXIDOPAMINE;

ADENOVIRUS; ARTICLE; CELL CULTURE; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; GENE THERAPY; GLIA CELL; NERVE DEGENERATION; NEUROPROTECTION; PARKINSON DISEASE; PRIORITY JOURNAL;

ADENOVIRIDAE; ANIMALS; CORPUS STRIATUM; DOPAMINE; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; HUMANS; MALE; MOLECULAR SEQUENCE DATA; NERVE DEGENERATION; NERVE GROWTH FACTORS; NERVE TISSUE PROTEINS; NEURONS; NEUROPROTECTIVE AGENTS; OXIDOPAMINE; PARKINSON DISEASE; PC12 CELLS; RATS; RATS, INBRED F344; SUBSTANTIA NIGRA; TRANSGENES;

EID: 0031019795     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.275.5301.838     Document Type: Article

References (40)

1. L.-F. H. Lin, D. H. Doherty, J. D. Lile, S. Bektesh, F. Collins, Science 260, 1130 (1993).
2. K. D. Beck et al., Nature 373, 339 (1995); A. Tomac et al., ibid., p. 335; C. M. Kearns and D. M. Gash, Brain Res. 672, 104 (1995); B. J. Hoffer et al., Neurosci. Lett. 182, 107 (1994); K. E. Bowenkamp et al., J. Comp. Neurol. 355, 479 (1995); D. M. Gash et al., Nature 380, 252 (1996); H. Sauer, C. Rosenblad, A. Bjorklund, Proc. Natl. Acad. Sci. U.S.A. 92, 8935 (1995).
3. K. D. Beck et al., Nature 373, 339 (1995); A. Tomac et al., ibid., p. 335; C. M. Kearns and D. M. Gash, Brain Res. 672, 104 (1995); B. J. Hoffer et al., Neurosci. Lett. 182, 107 (1994); K. E. Bowenkamp et al., J. Comp. Neurol. 355, 479 (1995); D. M. Gash et al., Nature 380, 252 (1996); H. Sauer, C. Rosenblad, A. Bjorklund, Proc. Natl. Acad. Sci. U.S.A. 92, 8935 (1995).
4. K. D. Beck et al., Nature 373, 339 (1995); A. Tomac et al., ibid., p. 335; C. M. Kearns and D. M. Gash, Brain Res. 672, 104 (1995); B. J. Hoffer et al., Neurosci. Lett. 182, 107 (1994); K. E. Bowenkamp et al., J. Comp. Neurol. 355, 479 (1995); D. M. Gash et al., Nature 380, 252 (1996); H. Sauer, C. Rosenblad, A. Bjorklund, Proc. Natl. Acad. Sci. U.S.A. 92, 8935 (1995).
5. K. D. Beck et al., Nature 373, 339 (1995); A. Tomac et al., ibid., p. 335; C. M. Kearns and D. M. Gash, Brain Res. 672, 104 (1995); B. J. Hoffer et al., Neurosci. Lett. 182, 107 (1994); K. E. Bowenkamp et al., J. Comp. Neurol. 355, 479 (1995); D. M. Gash et al., Nature 380, 252 (1996); H. Sauer, C. Rosenblad, A. Bjorklund, Proc. Natl. Acad. Sci. U.S.A. 92, 8935 (1995).
6. K. D. Beck et al., Nature 373, 339 (1995); A. Tomac et al., ibid., p. 335; C. M. Kearns and D. M. Gash, Brain Res. 672, 104 (1995); B. J. Hoffer et al., Neurosci. Lett. 182, 107 (1994); K. E. Bowenkamp et al., J. Comp. Neurol. 355, 479 (1995); D. M. Gash et al., Nature 380, 252 (1996); H. Sauer, C. Rosenblad, A. Bjorklund, Proc. Natl. Acad. Sci. U.S.A. 92, 8935 (1995).
7. K. D. Beck et al., Nature 373, 339 (1995); A. Tomac et al., ibid., p. 335; C. M. Kearns and D. M. Gash, Brain Res. 672, 104 (1995); B. J. Hoffer et al., Neurosci. Lett. 182, 107 (1994); K. E. Bowenkamp et al., J. Comp. Neurol. 355, 479 (1995); D. M. Gash et al., Nature 380, 252 (1996); H. Sauer, C. Rosenblad, A. Bjorklund, Proc. Natl. Acad. Sci. U.S.A. 92, 8935 (1995).
8. K. D. Beck et al., Nature 373, 339 (1995); A. Tomac et al., ibid., p. 335; C. M. Kearns and D. M. Gash, Brain Res. 672, 104 (1995); B. J. Hoffer et al., Neurosci. Lett. 182, 107 (1994); K. E. Bowenkamp et al., J. Comp. Neurol. 355, 479 (1995); D. M. Gash et al., Nature 380, 252 (1996); H. Sauer, C. Rosenblad, A. Bjorklund, Proc. Natl. Acad. Sci. U.S.A. 92, 8935 (1995).
9. 10, 50.
10. 10, 50.
11. L. A. Greene and A. S. Tischler, Proc. Natl. Acad. Sci. U.S.A. 73, 2424 (1976).
12. 2 in 0.01 M sodium acetate, pH 5.0, were added and absorbance at 405 nm was measured.
13. J. Engele and M. C. Bohn, Dev. Biol. 152, 363 (1992).
14. H. Sauer and W. H. Oertel, Neuroscience 59, 401 (1994).
15. 7 PFU/μl in 20% sucrose in PBS) were injected unilaterally dorsal to the SN at 0.5 μl/min at -5.3 mm AP, 1.8 mm ML, and -7.4 mm DV to the bregma. The needle was left in place for 5 min and withdrawn at 1 mm/min. 6-OHDA-HBr [16 μg of free base in 2.8 μl of ascorbic acid (0.2 mg/ml) in 0.9% saline] was injected unilaterally into the striatum at 0.5 μl/min at the same coordinates as FG. Rats were perfused with 100 ml of 0.9% saline followed by 300 ml of 4% paraformaldehyde in 0.1 M phosphate buffer, pH 7.4. After post-fix and cryoprotection, coronal sections were processed for TH immunofluorescence or TH immunocytochemistry with 1:1000 TH antibody (Chemicon, Temecula, CA). In addition, Ad lacZ transgene expression was followed by histochemistry with X-Gal [C. Cepko, in Molecular Neurobiological Techniques, A. A. Boulton, G. B. Baker, A. T. Campagnoni, Eds., vol. 16 of Neuromethods, A. A. Boulton and G. B. Baker, Eds. (Humana, Clifton, NJ, 1990), pp. 177-219.
16. 7 PFU/μl in 20% sucrose in PBS) were injected unilaterally dorsal to the SN at 0.5 μl/min at -5.3 mm AP, 1.8 mm ML, and -7.4 mm DV to the bregma. The needle was left in place for 5 min and withdrawn at 1 mm/min. 6-OHDA-HBr [16 μg of free base in 2.8 μl of ascorbic acid (0.2 mg/ml) in 0.9% saline] was injected unilaterally into the striatum at 0.5 μl/min at the same coordinates as FG. Rats were perfused with 100 ml of 0.9% saline followed by 300 ml of 4% paraformaldehyde in 0.1 M phosphate buffer, pH 7.4. After post-fix and cryoprotection, coronal sections were processed for TH immunofluorescence or TH immunocytochemistry with 1:1000 TH antibody (Chemicon, Temecula, CA). In addition, Ad lacZ transgene expression was followed by histochemistry with X-Gal [C. Cepko, in Molecular Neurobiological Techniques, A. A. Boulton, G. B. Baker, A. T. Campagnoni, Eds., vol. 16 of Neuromethods, A. A. Boulton and G. B. Baker, Eds. (Humana, Clifton, NJ, 1990), pp. 177-219.
17. D. L. Choi-Lundberg et al., data not shown.
18. D. N. Angelov, A. Gunkel, E. Stennert, W. F. Neiss, Glia 13, 113 (1995); L. Rinaman, C. E. Milligan, P. Levitt, Neuroscience 44, 765 (1991).
19. D. N. Angelov, A. Gunkel, E. Stennert, W. F. Neiss, Glia 13, 113 (1995); L. Rinaman, C. E. Milligan, P. Levitt, Neuroscience 44, 765 (1991).
20. 2. Tissue was sonicated in nine volumes of PBS, 0.1% Tween-20, 0.5% BSA, 2 mM EDTA, and protease inhibitors, then centrifuged at 40,000g for 12 min. The supernatant was used for GDNF (5) and β-Gal ELISA (5 Prime → 3 Prime, Boulder, CO), and RNA and DNA were isolated from the pellet with Tri Reagent (Molecular Research Center, Cincinnati, OH). RT-PCR and PCR with β-actin primers were performed as described (15), except that PCR conditions were 94°C for 30 s; 52°C for 45 s, and 72°C for 45 s. GDNF primers that recognize human, but not rat, GDNF(5′-GATAAACAAATGGCAGTGCT and 5′-AGCCTTCTATTTCTGGATAA) yielded a 269-base pair product with PCR conditions of 94°C for 30 s, 56°C for 45 s, and 72°C for 30 s. lacZ primers were as described [B. Lu, S. Gupta, H. Federoff, Hepatology 21, 752 (1995)]. PCR products from the linear range of amplification were quantified from ethidium bromide-stained gels with NIH Image.
21. P. Durbec et al., Nature 381, 789 (1996); S. Jing et al. Cell 85, 1113 (1996).
22. P. Durbec et al., Nature 381, 789 (1996); S. Jing et al. Cell 85, 1113 (1996).
23. J. J. S. Treanor et al., Nature 382, 80 (1996); M. Trupp et al., ibid. 381, 785 (1996).
24. J. J. S. Treanor et al., Nature 382, 80 (1996); M. Trupp et al., ibid. 381, 785 (1996).
25. E. Arenas, M. Trupp, P. Akerud, C. F. Ibanez, Neuron 15, 1465 (1995); A. Buj-Bello et al., ibid., p. 821; T. Ebendal, A. Tomac, B. J. Hoffer, L. Olson, J. Neurosci. Res. 40, 276 (1995); C. E. Henderson et al., Science 266, 1062 (1994); H. T. J. Mount et al., Proc. Natl. Acad. Sci. U.S.A. 92, 9092 (1995); M. Trupp et al., J. Cell Biol. 130, 137 (1995).
26. E. Arenas, M. Trupp, P. Akerud, C. F. Ibanez, Neuron 15, 1465 (1995); A. Buj-Bello et al., ibid., p. 821; T. Ebendal, A. Tomac, B. J. Hoffer, L. Olson, J. Neurosci. Res. 40, 276 (1995); C. E. Henderson et al., Science 266, 1062 (1994); H. T. J. Mount et al., Proc. Natl. Acad. Sci. U.S.A. 92, 9092 (1995); M. Trupp et al., J. Cell Biol. 130, 137 (1995).
27. E. Arenas, M. Trupp, P. Akerud, C. F. Ibanez, Neuron 15, 1465 (1995); A. Buj-Bello et al., ibid., p. 821; T. Ebendal, A. Tomac, B. J. Hoffer, L. Olson, J. Neurosci. Res. 40, 276 (1995); C. E. Henderson et al., Science 266, 1062 (1994); H. T. J. Mount et al., Proc. Natl. Acad. Sci. U.S.A. 92, 9092 (1995); M. Trupp et al., J. Cell Biol. 130, 137 (1995).
28. E. Arenas, M. Trupp, P. Akerud, C. F. Ibanez, Neuron 15, 1465 (1995); A. Buj-Bello et al., ibid., p. 821; T. Ebendal, A. Tomac, B. J. Hoffer, L. Olson, J. Neurosci. Res. 40, 276 (1995); C. E. Henderson et al., Science 266, 1062 (1994); H. T. J. Mount et al., Proc. Natl. Acad. Sci. U.S.A. 92, 9092 (1995); M. Trupp et al., J. Cell Biol. 130, 137 (1995).
29. E. Arenas, M. Trupp, P. Akerud, C. F. Ibanez, Neuron 15, 1465 (1995); A. Buj-Bello et al., ibid., p. 821; T. Ebendal, A. Tomac, B. J. Hoffer, L. Olson, J. Neurosci. Res. 40, 276 (1995); C. E. Henderson et al., Science 266, 1062 (1994); H. T. J. Mount et al., Proc. Natl. Acad. Sci. U.S.A. 92, 9092 (1995); M. Trupp et al., J. Cell Biol. 130, 137 (1995).
30. E. Arenas, M. Trupp, P. Akerud, C. F. Ibanez, Neuron 15, 1465 (1995); A. Buj-Bello et al., ibid., p. 821; T. Ebendal, A. Tomac, B. J. Hoffer, L. Olson, J. Neurosci. Res. 40, 276 (1995); C. E. Henderson et al., Science 266, 1062 (1994); H. T. J. Mount et al., Proc. Natl. Acad. Sci. U.S.A. 92, 9092 (1995); M. Trupp et al., J. Cell Biol. 130, 137 (1995).
31. D. L. Choi-Lundberg and M. C. Bohn, Dev. Brain Res. 85, 80 (1995).
32. S. Akli et al., Nature Genet. 3, 224 (1993); G. Bajocchi, S. H. Feldman, R. G. Crystal, A. Mastrangeli, ibid., p. 229; B. L. Davidson, E. D. Allen, K. F. Kozarsky, J. M. Wilson, B. J. Roessler, ibid., p. 219; G. Le Gal La Salle et al., Science 259, 988 (1993).
33. S. Akli et al., Nature Genet. 3, 224 (1993); G. Bajocchi, S. H. Feldman, R. G. Crystal, A. Mastrangeli, ibid., p. 229; B. L. Davidson, E. D. Allen, K. F. Kozarsky, J. M. Wilson, B. J. Roessler, ibid., p. 219; G. Le Gal La Salle et al., Science 259, 988 (1993).
34. S. Akli et al., Nature Genet. 3, 224 (1993); G. Bajocchi, S. H. Feldman, R. G. Crystal, A. Mastrangeli, ibid., p. 229; B. L. Davidson, E. D. Allen, K. F. Kozarsky, J. M. Wilson, B. J. Roessler, ibid., p. 219; G. Le Gal La Salle et al., Science 259, 988 (1993).
35. S. Akli et al., Nature Genet. 3, 224 (1993); G. Bajocchi, S. H. Feldman, R. G. Crystal, A. Mastrangeli, ibid., p. 229; B. L. Davidson, E. D. Allen, K. F. Kozarsky, J. M. Wilson, B. J. Roessler, ibid., p. 219; G. Le Gal La Salle et al., Science 259, 988 (1993).
36. A. P. Byrnes, J. E. Rusby, M. J. A. Wood, H. M. Charlton, Neuroscience 66, 1015 (1995).
37. S. K. Tripathy, H. B. Black, E. Goldwasser, J. M. Leiden, Nature Med. 2, 545 (1996).
38. Y. Yang et al., Nature Genet. 7, 362 (1994).
39. C. W. Olanow, J. Neural Transm. 91, 161 (1993).
40. We thank R. Giuliano for assistance with cell culture, R. Anderson for assistance with preparation of viral stocks, J. Qian for neuropathological evaluation, and H. Federoff and W. Freed for their suggestions on the manuscript. Supported by NIH grants NS31957 (M.C.B.) and T32AG00107 (H.M.), the National Parkinson's Foundation, and Genetic Therapy, Inc.